Stock Price, News, Quote and Profile of BIORA THERAPEUTICS INC(NASDAQ:BIOR) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIORA THERAPEUTICS INC

NASDAQ:BIOR (5/15/2024, 7:00:01 PM)

After market: 0.74 +0.03 (+3.5%)

0.715

-0.02 (-3.1%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap25.65M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 54 full-time employees. The company went IPO on 2020-06-19. The firm's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The firm's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.